World's Best Scientists 2026 revealed!
Roger Schibli

Roger Schibli

D-Index & Metrics

Chemistry

D-Index
74
Citations
19597
World Ranking
4690
National Ranking
107

Roger Schibli publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Roger Schibli sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 371 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Roger Schibli D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Roger Schibli sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 74 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Roger Schibli is a researcher affiliated with ETH Zurich in Switzerland. Their academic contributions span primarily within the field of Medicine, with a notable focus on subfields such as Radiology, Nuclear Medicine and Imaging, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, and Epidemiology.

Their research work extensively covers several major topics, including Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications, Peptidase Inhibition and Analysis, Neuroendocrine Tumor Research Advances, Prostate Cancer Treatment and Research, Lung Cancer Research Studies, and Neuroscience and Neuropharmacology Research.

Schibli's recent papers include:

  • Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease (2021, Pharmaceuticals)
  • Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity (2020, Theranostics)
  • Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms (2021, European Journal of Nuclear Medicine and Molecular Imaging)
  • First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC (2021, Journal of Nuclear Medicine)
  • On the consensus nomenclature rules for radiopharmaceutical chemistry - Reconsideration of radiochemical conversion (2020, Nuclear Medicine and Biology)

Frequent co-authors in Schibli's publications include Cristina Müller, Linjing Mu, Nicholas P. van der Meulen, Martin Béhé, and Pascal V. Grundler. These collaborative efforts indicate a consistent teamwork presence in their research output.

Schibli has contributed to various publication venues, with the largest number of works appearing in Nuclear Medicine and Biology, European Journal of Nuclear Medicine and Molecular Imaging, and Journal of Nuclear Medicine. Other publication venues include Cancers and EJNMMI Research.

  • Nuclear Medicine and Biology
  • European Journal of Nuclear Medicine and Molecular Imaging
  • Journal of Nuclear Medicine
  • Cancers
  • EJNMMI Research

The diversity of Schibli's research topics and publication outlets illustrates a multidisciplinary approach primarily anchored in nuclear medicine and oncological imaging techniques, with applications ranging from neurodegenerative disease imaging to cancer treatment research. This profile reflects an ongoing engagement with both fundamental radiopharmaceutical chemistry and applied clinical imaging.

Best Publications

  • A Novel Organometallic Aqua Complex of Technetium for the Labeling of Biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in Aqueous Solution and Its Reaction with a Bifunctional Ligand

    Roger Alberto;Roger Schibli;and André Egli;August P. Schubiger

  • Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+.

    Roger Alberto;Kirstin Ortner;Nigel Wheatley;Roger Schibli

  • Metal chelating systems synthesized using the copper(I) catalyzed azide-alkyne cycloaddition.

    Harriet Struthers;Thomas L. Mindt;Roger Schibli

  • Influence of the denticity of ligand systems on the in vitro and in vivo behavior of (99m)Tc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules.

    R Schibli;R La Bella;R Alberto;E Garcia-Garayoa

  • Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M=Re, Tc) directed towards radiopharmaceutical application

    Roger Alberto;Roger Schibli;Robert Waibel;Ulrich Abram

  • "Click to chelate": synthesis and installation of metal chelates into biomolecules in a single step.

    Thomas L. Mindt;Harriet Struthers;Luc Brans;Todor Anguelov

  • Current use and future potential of organometallic radiopharmaceuticals

    Roger Schibli;August P. Schubiger

  • Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex.

    R Waibel;R Alberto;J Willuda;R Finnern

  • Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase.

    Simone Jeger;Kurt Zimmermann;Alain Blanc;Jürgen Grünberg

  • Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.

    Christian Zahnd;Martin Kawe;Michael T. Stumpp;Christine de Pasquale

  • Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

    Patrick Dennler;Aristeidis Chiotellis;Eliane Fischer;Delphine Brégeon

  • In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(eta(6)-p-cymene)-Cl-2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

    Andrea Weiss;Andrea Weiss;Robert H. Berndsen;Maxime Dubois;Cristina Müller

  • A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β−-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

    Christina Müller;Konstantin Zhernosekov;Ulli Köster;Karl Johnston

  • Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor [(188)Re(H(2)O)(3)(CO)(3)](+) and synthesis of tailor-made bifunctional ligand systems.

    Roger Schibli;Rolf Schwarzbach;Roger Alberto;Kirstin Ortner

  • “Click-to-Chelate”: Design and Incorporation of Triazole-Containing Metal-Chelating Systems into Biomolecules of Diagnostic and Therapeutic Interest

    Harriet Struthers;Harriet Struthers;Bernhard Spingler;Thomas L. Mindt;Roger Schibli;Roger Schibli

  • Transplantation and Tracking of Human-Induced Pluripotent Stem Cells in a Pig Model of Myocardial Infarction Assessment of Cell Survival, Engraftment, and Distribution by Hybrid Single Photon Emission Computed Tomography/Computed Tomography of Sodium Iodide Symporter Transgene Expression

    Christian Templin;Robert Zweigerdt;Kristin Schwanke;Ruth Olmer

  • Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice

    Cristina Müller;Maruta Bunka;Maruta Bunka;Stephanie Haller;Ulli Köster

  • Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity.

    A Egli;R Alberto;L Tannahill;R Schibli

  • Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

    Cristina Müller;Christoph A. Umbricht;Nadezda Gracheva;Viviane J. Tschan

  • The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy

    Silvia Lehenberger;Christoph Barkhausen;Susan Cohrs;Eliane Fischer

  • Folic Acid Conjugates for Nuclear Imaging of Folate Receptor–Positive Cancer

    Cristina Müller;Roger Schibli

  • Reactions with the technetium and rhenium carbonyl complexes (NEt4)2[MX3(CO)3]. Synthesis and structure of [Tc(CN-But)3(CO)3](NO3) and (NEt4)[Tc2(μ-SCH2CH2OH)3(CO)6]

    Roger Alberto;Roger Schibli;P. August Schubiger;Ulrich Abram

Frequent Co-Authors

Andreas Türler
Andreas Türler University of Bern
Roger Alberto
Roger Alberto University of Zurich
Dirk Tourwé
Dirk Tourwé Vrije Universiteit Brussel
Philipp A. Kaufmann
Philipp A. Kaufmann University of Zurich
Wynn A. Volkert
Wynn A. Volkert University of Missouri
Bernhard Spingler
Bernhard Spingler University of Zurich
Rolf Gruetter
Rolf Gruetter École Polytechnique Fédérale de Lausanne
Oliver Distler
Oliver Distler University of Zurich
Marion de Jong
Marion de Jong Erasmus University Rotterdam
Alfred Buck
Alfred Buck University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens doors to diverse career options, often requiring specialized education and training. For example, those interested in combining science with sales may explore roles like pharmaceutical representatives. Understanding how much do pharmaceutical reps make can help gauge the financial prospects in this lucrative field.

For students aiming for a more clinical path, becoming a pharmacist is a popular choice. Insight into how to become a pharmacist salary offers a realistic view of the commitment needed and the rewards involved.

Another specialized career is becoming an autopsy technician, which combines chemistry with forensic investigation. Learning about the autopsy tech salary and educational requirements can help students determine if this path suits their interests.

For those interested in a broader forensic science education, there are many affordable programs available online. Exploring the options within online forensic science degree programs offers flexibility and accessibility for busy learners.

Best Scientists Citing Roger Schibli

Trending Scientists

Recently Published Articles